Effect of SGLT2 inhibitor (Lusefi) on diabetic nephropathy Stratified analysis based on different original renal function category

Effect of SGLT2 inhibitor (Lusefi) on diabetic nephropathy Stratified analysis based on different original renal function category - CHAT-Lu

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029975

Enrollment

100

Registered

2018-01-04

Start date

2018-01-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

Oral treatment of SGLT2 inhibitor(Lusefi)2.5mg once a day for 104 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetes mellitus(HbA1c 6.5%<=) pre eGFR(30-90ml/min/1.73m2) age 20 years old <=

Exclusion criteria

Exclusion criteria: past use of SGLT2 inhibitor severe ketoacidosis,diabetes coma,type1diabetes severe infection,pre and post operation,severe in injury pregnancy,lactation,potential pregnancy

Design outcomes

Primary

Measure	Time frame
Renal function at 104th week post SGLT2 inhibitor treatment Stratified analysis based on different original renal function category	—

Countries

Japan

Contacts

Public ContactHidenori Urata

Fukuoka University Chikushi Hospital Cardiovascular internal medicine

uratah@fukuoka-u.ac.jp092-921-1011

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026